Loading
Micrornas / RNA, Long Noncoding / Disease Progression · Journal article
Hypertension in Pregnancy · August 16, 2026
Encouraging direction, but not yet definitive.
This single-centre case–control study identifies MIR210HG as a peripheral blood biomarker upregulated in early-onset preeclampsia, particularly in the PE–fetal growth restriction subtype, and provides in vitro evidence that MIR210HG regulates CDHR5 expression in trophoblastic and endothelial cells. The finding is mechanistically plausible but the pathogenic pathway remains incompletely characterised, and the diagnostic utility requires prospective validation in independent cohorts.
Case–control study with in vitro mechanistic validation. 88 preeclampsia patients (case group) and 81 normal pregnant women (control group) from the Affiliated Hospital of Qingdao University, enrolled during January 2020–December 2021. Specific inclusion/exclusion criteria, PE severity classification, and gestational age distribution not stated.. Intervention: MIR210HG knockdown via siRNA transfection; CDHR5 knockdown via siRNA; MIR210HG overexpression via plasmid transfection in cultured trophoblasts and endothelial cells.. Compared with: Control cells (transfected with control/scrambled siRNA or empty vector); normal pregnant women as clinical control group.. n = 169. Affiliated Hospital of Qingdao University, China.
MIR210HG expression was specifically upregulated in peripheral blood of early-onset PE patients with superior diagnostic efficacy for PE–fetal growth restriction subtype. CDHR5 was upregulated in PE-associated placental tissues (P = 0.004). MIR210HG knockdown reduced CDHR5 expression in Bewo trophoblasts (P = 0.019) and JEG3 cells (P = 0.006).
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
If validated prospectively, peripheral blood MIR210HG measurement could offer a non-invasive screening tool for early-onset preeclampsia and phenotypic stratification (particularly PE–fetal growth restriction). Current evidence is insufficient to recommend clinical use; diagnostic accuracy metrics (sensitivity, specificity, ROC-AUC) are mentioned but not reported quantitatively.
A real result from a sound but limited single-centre observational study with in vitro validation, identifying a biomarker with potential diagnostic utility that needs prospective validation.
As stated by the source record.
Quoted from the source exactly as published.
If validated prospectively, peripheral blood MIR210HG measurement could offer a non-invasive screening tool for early-onset preeclampsia and phenotypic stratification (particularly PE–fetal growth restriction). Current evidence is insufficient to recommend clinical use; diagnostic accuracy metrics (sensitivity, specificity, ROC-AUC) are mentioned but not reported quantitatively.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Objective. Early diagnosis of preeclampsia (PE) remains challenging. We previously linked the long non-coding (lnc) RNA MIR210HG to pathological placental development. Here, we investigated its differential expression, pathophysiological phenotypic specificity, and non-invasive diagnostic potential for PE in the peripheral blood and placental tissue.Methods. We enrolled 88 PE patients (case group) and 81 normal pregnant women (control group) from the Affiliated Hospital of Qingdao University during January 2020-December 2021. MIR210HG expression was detected via RT-PCR and western blotting, and was modulated using siRNA/overexpression plasmid transfection in human trophoblasts and vascular endothelial cells.Results. MIR210HG expression was specifically upregulated in the peripheral blood of patients with early-onset PE, with superior diagnostic efficacy for the PE-fetal growth restriction subtype. Additionally, CDHR5 was upregulated in PE-associated placental tissues (P = 0.004). Cellular assays confirmed that MIR210HG knockdown reduced CDHR5 expression in trophoblasts and endothelial cells (Bewo: P = 0.019; JEG3: P = 0.006), and CDHR5 knockdown also downregulated MIR210HG expression (Bewo: P = 0.023).Conclusion. Therefore, MIR210HG may contribute to placental pathological injury by regulating CDHR5, though the pathogenic mechanism remains unclear. In contrast to the invasive and lagging placental-derived lncRNA biomarkers reported in previous studies, peripheral blood MIR210HG allows for non-invasive monitoring during pregnancy, making it more clinically applicable for early screening and phenotypic stratification of PE.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.